Collaborative Research Funding for Relapsed and Refractory Pediatric Brain Tumors offers Hope
Memorial Sloan Kettering Cancer Center (with 11 additional treatment sites)
After co-funding a highly successful international clinical trial that opened for international enrollment in 2017, A Kids’ Brain Tumor Cure Foundation, Solving Kids’ Cancer and the Ty Louis Campbell (TLC) Foundation have teamed up again to announce their joint financial support of a Phase 1 clinical trial that will test the safety and efficacy of a new immunotherapy produced by Apexigen to treat of children with brain tumors.
The study will test safety and efficacy of a promising new agent, APX-005M CD40, against antibodies in children with brain tumors. This first-in-class immunotherapy has the potential for significant efficacy in children with recurrent or refractory tumors in the central nervous system, and it is a new therapy option for children with newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), a type of brain cancer that is 100% terminal upon diagnosis. It has been rolled out via the Pediatric Brain Tumor Consortium (PBTC), a collective group of multidisciplinary research organizations, which allows more children access to this promising new treatment option in twelve reputable institutions across the country.
This is the second immunotherapy trial being funded by these three like-minded nonprofits as a result of their mutual support of primary investigator, Dr. Ira Dunkel, Memorial Sloan Kettering Cancer Center, and their confidence in multi-faceted collaborative efforts as a progressive way forward. The clinical trial is currently open for enrollment, and more information can be found here on clinicaltrials.gov.
“Collaboration is the driving force behind making progress in research, faster,” said Dr. Ira Dunkel, Memorial Sloan Kettering Cancer Center. “Similar to the efforts of nonprofit organizations that have been partnering for years to increase their impact, a team of researchers founded the Pediatric Brain Tumor Consortium in 1999 to advance progress through multi-center, multidisciplinary, innovative studies with designs and analyses based on its shared high standard of statistical science.”
Dr. Dunkel’s most recently shared that trial accrual is going well and taking place in a timely fashion, hoping to complete the non-DIPG accruals by mid-2019 (which can often be a challenge in other pediatric brain tumor trials). The dosing levels have been increased three times, and it is predicted that the DIPG arm will start based on the dose findings from the non-DIPG participants.
Collectively, these three like-minded nonprofits made a contribution of $120,000 to help make this trial available to children battling brain tumors, today. It is currently open for enrollment, providing a viable option with far less toxicity than chemotherapy to children in need of alternative options.